Acumen announces Phase 1 INTERCEPT-AD study publication

Acumen (ABOS) Pharmaceuticals announced that the Journal of Prevention of Alzheimer’s Disease published the results of the Phase 1 INTERCEPT-AD clinical trial demonstrating that sabirnetug was generally well-tolerated with dose- and exposure-dependent target engagement and reduction in amyloid plaques. “The robust data package generated by this Phase 1 study provides important evidence of sabirnetug’s safety profile, further confirms the mechanism of action of sabirnetug and establishes the foundation for our ongoing Phase 2 ALTITUDE-AD clinical trial, including the doses used in ALTITUDE-AD,” said Eric Siemers, M.D., Chief Medical Officer of Acumen. “We are pleased to highlight the strength of our study design and the creation of advanced tools for drug development, including an assay that can detect very small amounts of sabirnetug bound to toxic soluble amyloid beta oligomers in human cerebrospinal fluid.”